Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
M&A Deal

MaxCyte Shares Rise 6% After MaxCyte to Acquire Akron BioProducts in $125 Million Strategic Deal

MaxCyte to Acquire Akron BioProducts in $125 Million Strategic Deal

+6.92% $1.30 when we broke this story → $1.39 at 9:38 AM ET, 10 Nov 2026

MaxCyte has entered into a definitive agreement to acquire Akron BioProducts LLC for $125 million in total consideration, including cash, stock, and deferred payments. The acquisition of the GMP-grade reagent supplier is intended to expand MaxCyte's capabilities in the cell therapy manufacturing market and significantly enhance its revenue profile.

Welding, sparks, engineering, working. Stock photo illustrating MaxCyte's M&A deal story.
MAXCYTE, INC. · Healthcare · Photo: TheOtherKev / Pixabay
Key numbers
Deal value$125M
Share of market cap93.2%
Share of annual revenue378.5%

Key highlights

  • Total consideration includes $105 million in cash at closing and $20 million in deferred payments
  • MaxCyte will issue approximately 20.6 million shares of common stock to the sellers
  • The acquisition is expected to nearly double MaxCyte's current annual revenue upon integration
  • Full-year 2026 revenue guidance was raised to at least $34.5 million following the announcement
  • The deal is projected to close before the end of 2026 subject to regulatory approvals

What Is the Deal?

MaxCyte, Inc. has entered into a definitive securities purchase agreement to acquire all outstanding equity interests of Akron BioProducts LLC from affiliates of Arcline Investment Management. The acquisition involves an upfront cash payment of $105 million, approximately 20.6 million shares of MaxCyte common stock, and $20 million in guaranteed deferred cash. Akron BioProducts is a prominent supplier of GMP-grade reagents and ancillary materials, which are critical components in the manufacturing of next-generation cell therapeutics. The transaction is scheduled to close by the end of 2026, pending customary closing conditions and regulatory clearance under the Hart-Scott-Rodino Act.

Deal Structure & Terms

  • Cash component consists of $105 million due at closing, subject to customary working capital adjustments
  • Deferred cash payments of $10 million each are scheduled for the first business days of 2028 and 2029
  • Stock consideration involves 20,639,733 shares of MXCT common stock issued to the sellers
  • A six-month lock-up period will apply to the shares issued as part of the transaction
  • MaxCyte obtained a conditional binder for representations and warranties insurance for post-closing recourse

Strategic Rationale

“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”

Maher Masoud, President and CEO of MaxCyte

Financial Context

The acquisition arrives as MaxCyte reports strong operational momentum, with third-quarter 2026 revenue reaching $10.2 million, a 49% increase compared to the prior year. The company core business revenue grew 27% to $8.2 million, while Strategic Platform License revenue contributed $2.0 million. By acquiring Akron, MaxCyte expects to nearly double its annual revenue profile. The $125 million deal value is significant relative to MaxCyte current market capitalization of approximately $134.2 million. Following the deal announcement, the company raised its full-year 2026 revenue guidance to at least $34.5 million, anticipating a return to sustained full-year growth.

MAXCYTE, INC. share price · last month
Line chart of MAXCYTE, INC.'s share price over the last month, from $1.30 on 19 Oct → $1.18 on 16 Nov; our story on 10 Nov at $1.30.

Down 9.2% since our story on 10 Nov: $1.30 when we broke it → $1.18 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$1.30
20 Oct$1.43
21 Oct$1.47
22 Oct$1.43
23 Oct$1.40
26 Oct$1.51
27 Oct$1.54
28 Oct$1.71
29 Oct$1.73
30 Oct$1.59
2 Nov$1.45
3 Nov$1.46
4 Nov$1.39
5 Nov$1.31
6 Nov$1.26
9 Nov$1.30
10 Nov$1.13
11 Nov$1.10
12 Nov$1.19
13 Nov$1.19
16 Nov$1.18

Industry Landscape

The cell therapy sector is increasingly focused on vertical integration to secure the supply chain for critical raw materials. GMP-grade reagents, such as those supplied by Akron BioProducts, are essential for maintaining the safety and efficacy of therapeutic products during the scale-up process. As cell therapy developers move toward late-stage clinical trials and commercialization, demand for high-quality ancillary materials has intensified. This acquisition positions MaxCyte as a comprehensive solutions provider, moving beyond its core electroporation technology to offer a broader suite of products required for the entire cell therapy manufacturing lifecycle.

Management commentary

“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”

Maher Masoud, President and CEO of MaxCyte
MAXCYTE, INC. · financial snapshot
Share price$1.30
Market cap$134M
Revenue (annual)$33M
1-month price change+27.45%
SectorHealthcareMedical Devices

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by MaxCyte, Inc. announcing the acquisition of Akron BioProducts LLC.

Read the filing ↗

Track MAXCYTE, INC. live

Get the next MAXCYTE, INC. SEC filing seconds after it lands.

More in M&A & Deals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.